← Back to Home

Dual Signals for Weight Loss and Glycemic Control: Petrelintide Phase 2 Trial Shows Mean Weight Loss of Up to 9.2% at 28 Weeks

Targeting amylin signaling for weight management, petrelintide has shown preliminary benefits in patients with type 2 diabetes; however, the durability of its efficacy and its safety remain questions for complete data and larger trials.

By SURL BioNews

For people living with both excess weight and type 2 diabetes, weight and blood glucose are two interconnected issues in treatment. Zealand Pharma announced on October 7 that petrelintide, an investigational drug being jointly developed with Roche, met the primary endpoint in the Phase 2 ZUPREME-2 study: after 28 weeks of treatment, mean weight reductions in all three dose groups were significantly greater than with placebo, and there were also signals of improvement in glycated hemoglobin.

Petrelintide is a long-acting human amylin analog administered once weekly by subcutaneous injection. Amylin is produced by pancreatic β cells and released alongside insulin after meals, helping regulate satiety. The drug aims to use this physiological signal to help control weight; this study further examined how much benefit it could provide in a population with diabetes.

This US multicenter, randomized, double-blind, placebo-controlled trial enrolled 220 people, alongside reduced calorie intake and increased physical activity. HCPLive added that participants had to have been diagnosed with type 2 diabetes at least 180 days before screening, have a BMI of at least 27, and be taking metformin, with concurrent use of an SGLT2 inhibitor permitted. Doses were increased every four weeks, with a dose-escalation period of up to 16 weeks. Treatment continued through week 28, followed by follow-up through week 38.

Under the efficacy estimand reported by the company, mean weight loss at week 28 ranged from 7.4% to 9.2% across the three petrelintide groups, compared with 2.0% in the placebo group. The highest figure, 9.2%, represents the mean reduction in one treatment group; it does not mean that every participant achieved this figure. The company said results under a separate treatment-regimen estimand were broadly consistent, but full details of the analyses have yet to be released.

The blood glucose figures also require a clear distinction between comparison baselines. Glycated hemoglobin (HbA1c) decreased by up to 0.65 percentage points from baseline in the petrelintide groups, while it increased by 0.23 percentage points in the placebo group. After subtracting the change in the placebo group, reductions across the treatment groups ranged from 0.61 to 0.88 percentage points. HCPLive also reported these adjusted figures. This supports the possibility that the drug may improve both weight and blood glucose, but it does not yet establish whether the risk of long-term complications is reduced.

Regarding tolerability, the company said no unexpected safety signals were identified. The most common adverse events were gastrointestinal, mostly mild, and concentrated during dose escalation. The proportion discontinuing treatment because of gastrointestinal adverse events was 1.9% in the petrelintide groups and 1.7% in the placebo group. Discontinuation rates offer clues about treatment tolerability, but cannot replace complete data on adverse-event frequency, severity, and long-term safety.

Zealand and Roche have initiated a Phase 3 development program expected to enroll approximately 7,000 people across three trials, covering different metabolic and cardiovascular disease backgrounds. The information released so far remains a summary of the topline results, with complete ZUPREME-2 data expected to be presented at a subsequent scientific meeting. This study did not directly compare petrelintide with other weight-loss drugs. Whether efficacy can be sustained, and the benefits and risks in a larger population, will be key questions for the next stage.

References

  1. Zealand Pharma / GlobeNewswire
  2. HCPLive